{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:08:48Z","timestamp":1771272528922,"version":"3.50.1"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s10072-023-07122-y","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T16:02:29Z","timestamp":1698163349000},"page":"1307-1309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efgartigimod improves triple-negative myasthenia gravis"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-3791","authenticated-orcid":false,"given":"Rita","family":"Frangiamore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0744-7238","authenticated-orcid":false,"given":"Elena","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9081-6462","authenticated-orcid":false,"given":"Fiammetta","family":"Vanoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8239-8830","authenticated-orcid":false,"given":"Francesca","family":"Andreetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-5737","authenticated-orcid":false,"given":"Renato","family":"Mantegazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-5224","authenticated-orcid":false,"given":"Carlo","family":"Antozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"7122_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/ITT.S377056","volume":"12","author":"SS Nair","year":"2023","unstructured":"Nair SS, Jacob S (2023) Novel immunotherapies for myasthenia gravis. Immunotargets Ther 12:25\u201345","journal-title":"Immunotargets Ther"},{"key":"7122_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102366","volume":"18","author":"AW Zuercher","year":"2019","unstructured":"Zuercher AW, Spring R, Morelli BA, Rowe T, Kasermann F (2019) Next-generation Fc receptor-targeting biologics for autoimmune diseases. Autoimmun Rev 18:102366","journal-title":"Autoimmun Rev"},{"key":"7122_CR3","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","volume":"92","author":"JF Howard","year":"2019","unstructured":"Howard JF, Bril V, Burns TM et al (2019) Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology 92:e2661-2673","journal-title":"Neurology"},{"key":"7122_CR4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalized myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20:526\u2013536","journal-title":"Lancet Neurol"},{"key":"7122_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA (2022) Efgartigimod: first approval. Drugs 82:341\u2013348","journal-title":"Drugs"},{"key":"7122_CR6","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/WCO.0000000000001088","volume":"35","author":"G Masi","year":"2022","unstructured":"Masi G, O\u2019Connor KC (2022) Novel pathological insights in autoimmune myasthenia gravis. Curr Opin Neurol 35:586\u2013596","journal-title":"Curr Opin Neurol"},{"key":"7122_CR7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ncl.2018.01.006","volume":"36","author":"C Barnett","year":"2018","unstructured":"Barnett C, Herbelin L, Dimachkie MM, Barohn RJ (2018) Measuring clinical treatment response in myasthenia gravis. Neurol Clin 36:339\u2013353","journal-title":"Neurol Clin"},{"key":"7122_CR8","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/mus.25198","volume":"54","author":"TM Burns","year":"2016","unstructured":"Burns TM, Sadjadi R, Utsugisawa K et al (2016) International clinimetric evaluation of the MG-Qol15, resulting in slight revision and subsequent validation of the MG-Qol15r. Muscle Nerve 54:1015\u20131022","journal-title":"Muscle Nerve"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07122-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-07122-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07122-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T02:05:43Z","timestamp":1707530743000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-07122-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["7122"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-07122-y","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]},"assertion":[{"value":"15 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.F. received support for congress participation from Argenx, Biogen, Catalyst, Merck, Momenta, Novartis, and Sanofi Genzyme. F.V. received support for congress participation from Biogen, Kedrion, and Sanofi Genzyme. R.M. received fees and honoraria for meeting, travel, and advisory board from Alexion, Argenx, Biomarin, Catalyst, Merck Serono, UCB.C.A. C.A. received funding for travel, meeting attendance, and advisory board participation from Alexion, Momenta Sanofi, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Ethics Committee of Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta requires the patients\u2019 consent for case report publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}